Analyzing Spectaire (NASDAQ:SPEC) & Callitas Health (OTCMKTS:MPHMF)

Callitas Health (OTCMKTS:MPHMFGet Free Report) and Spectaire (NASDAQ:SPECGet Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Analyst Ratings

This is a summary of recent recommendations and price targets for Callitas Health and Spectaire, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Callitas Health 0 0 0 0 0.00
Spectaire 0 1 0 0 2.00

Spectaire has a consensus price target of $2.50, indicating a potential upside of 5,713.95%. Given Spectaire’s stronger consensus rating and higher possible upside, analysts plainly believe Spectaire is more favorable than Callitas Health.

Profitability

This table compares Callitas Health and Spectaire’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Callitas Health N/A N/A N/A
Spectaire N/A -81.22% 304.57%

Volatility and Risk

Callitas Health has a beta of -3.5, suggesting that its stock price is 450% less volatile than the S&P 500. Comparatively, Spectaire has a beta of -0.46, suggesting that its stock price is 146% less volatile than the S&P 500.

Earnings and Valuation

This table compares Callitas Health and Spectaire”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Callitas Health $530,000.00 N/A -$1.28 million N/A N/A
Spectaire N/A N/A $8.95 million N/A N/A

Spectaire has lower revenue, but higher earnings than Callitas Health.

Institutional & Insider Ownership

26.6% of Spectaire shares are held by institutional investors. 25.4% of Spectaire shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Spectaire beats Callitas Health on 7 of the 9 factors compared between the two stocks.

About Callitas Health

(Get Free Report)

Callitas Health, Inc. is a clinical stage company. It engages in the development of technologies for obesity, weight management, and female health and wellness. The company focuses on developing technologies for weight management, female sexual health and wellness, cannabis delivery technologies and other proprietary drugs. It launched product ToConceive in North America. The firm researches, develops and business development processes for its other OTC products, CannaMint strips and orphan drug technologies. Callitas Health was founded on March 11, 2003 and is headquartered in Newport, KY.

About Spectaire

(Get Free Report)

Spectaire Holdings Inc. provides solutions that measure, manage, and reduce carbon dioxide equivalent and other greenhouse gas emissions. The company offers AireCore, an integrated hardware, software, and data platform for logistics and supply chain players that uses mass spectrometry to directly measure their emissions. It serves the logistics, energy, agriculture, academics, and indoor air industries. The company is based in Watertown, Massachusetts.

Receive News & Ratings for Callitas Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Callitas Health and related companies with MarketBeat.com's FREE daily email newsletter.